FDA warns of cardiac risk with stress test agents

November 22, 2013
FDA warns of cardiac risk with stress test agents

(HealthDay)—The use of cardiac nuclear stress test agents comes with a rare but serious risk of heart attack and death, according to a warning sent by the U.S. Food and Drug Administration to health care professionals.

Lexiscan (regadenoson) and Adenoscan (adenosine), used in cardiac stress tests in patients who cannot exercise adequately, help identify coronary artery disease by dilating heart arteries and increasing blood flow. The risk stems from reduced blood flow to obstructed areas, which may result in potentially fatal .

The FDA has approved drug label changes for the two drugs to highlight these risks and update recommendations for their use. At this time, it is not clear if there is any difference in risk between Lexiscan and Adenoscan.

According to the agency, should "screen all candidates for their suitability to receive Lexiscan or Adenoscan. Avoid using these drugs in patients with signs or symptoms of unstable angina or cardiovascular instability, as these patients may be at greater risk for serious cardiovascular adverse reactions."

Explore further: Physical fitness improves survival, prevents some heart attacks

More information: More Information

Related Stories

Recommended for you

Are vegetarian diets heart-healthier?

October 18, 2016

(HealthDay)—Vegetarians are assumed to be healthier than carnivores, but a new study questions that assumption. It found meat eaters had no significantly greater risk of heart disease over 10 years compared to those who ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.